SEARCH

SEARCH BY CITATION

References

  • 1
    Buyue Y, Misenheimer TM, Sheehan JP. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. J Thromb Haemost 2012; 10: 208698.
  • 2
    Oscarsson LG, Pejler G, Lindahl U. Location of the antithrombin-binding sequence in the heparin chain. J Biol Chem 1989; 264: 296304.
  • 3
    Kusche M, Torri G, Casu B, Lindahl U. Biosynthesis of heparin. Availability of glucosaminyl 3-O-sulfation sites. J Biol Chem 1990; 265: 7292300.
  • 4
    Garvin S, FitzGerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010; 111: 84955.
  • 5
    Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 86773.
  • 6
    Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695702.